

# Distribution Fact Sheet

## Network Specialty Pharmacies

NEMLUVIO® (nemolizumab-ilto) is available through a limited distribution network of specialty pharmacies. Our specialty pharmacy network provides enhanced service offerings so that you and your patients are supported throughout the entire NEMLUVIO access journey.

Specialty Pharmacy	Phone Number	Fax
AcariaHealth	800-511-5144	877-541-1503
Accredo Health Group, Inc.	866-839-2162	866-531-1025
Amber Specialty Pharmacy	888-370-1724	877-645-7514
BioPlus Specialty Pharmacy	800-292-0744	800-269-5493
Blue Sky Specialty Pharmacy	866-822-0103	833-898-3992
CenterWell Specialty Pharmacy	800-486-2668	877-405-7940
CVS Specialty	800-237-2767	800-323-2445
Kroger Specialty Pharmacy	888-355-4191	888-355-4192
Lumicera Health Services	855-847-3553	855-847-3558
Optum Specialty	855-427-4682	877-342-4596
Senderra	855-460-7928	888-777-5645
Walgreens Specialty Pharmacy	888-347-3416	877-231-8302

Please see Important Safety Information on page 3 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

## Specialty Distributor


NEMLUVIO is available for physician offices to order through Cencora. Please note that Cencora is our exclusive distribution partner for physicians utilizing the buy & bill model **only**. To set up an account with Cencora, please call customer service at 1-800-746-6273.

### Cencora Ordering Information

Phone Number	Fax	Email	Website
1-800-746-6273	1-800-547-9413	service@asdhealthcare.com	www.asdhealthcare.com/contact-us

## Product Information<sup>1</sup>

Presentation	Pack Size	NDC	Dosage Strength
Pre-filled pen	Pack of 1 pen	0299-6220-15	30 mg/0.49 mL



NDC, National Drug Code.

Reference: 1. NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.

Please see Important Safety Information on page 3 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

## IMPORTANT SAFETY INFORMATION

**Indications:** NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

- the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
- the treatment of adults with prurigo nodularis.

**Contraindication:** Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

**Warnings/Precautions:** Hypersensitivity reactions have been reported with NEMLUVIO use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. **Adverse Events:** Most common adverse reactions (incidence  $\geq 1\%$ ) are:

- **Atopic Dermatitis:** headache (including migraine), arthralgia, urticaria, and myalgia.
- **Prurigo Nodularis:** headache, dermatitis atopic, eczema, and eczema nummular.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please see accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.